GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Easton Pharmaceuticals Inc (OTCPK:EAPH) » Definitions » Piotroski F-Score

Easton Pharmaceuticals (Easton Pharmaceuticals) Piotroski F-Score : 0 (As of May. 23, 2024)


View and export this data going back to . Start your Free Trial

What is Easton Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Easton Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Easton Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


Easton Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Easton Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easton Pharmaceuticals Piotroski F-Score Chart

Easton Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec18 Dec19 Dec20
Piotroski F-Score
Get a 7-Day Free Trial 5.00 5.00 3.00 3.00 4.00

Easton Pharmaceuticals Quarterly Data
Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec18 Dec19 Dec20 Mar21 Jun21 Sep21
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 3.00 4.00 5.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep21) TTM:Last Year (Dec19) TTM:
Net Income was 0 + -0.097 + -0.08 + -0.084 = $-0.26 Mil.
Cash Flow from Operations was 0 + -0.079 + -0.003 + -0.059 = $-0.14 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Dec19)
to the end of this year (Sep21) was
(17.172 + 10.192 + 9.831 + 9.898 + 9.968) / 5 = $11.4122 Mil.
Total Assets at the begining of this year (Dec19) was $17.17 Mil.
Long-Term Debt & Capital Lease Obligation was $2.84 Mil.
Total Current Assets was $0.00 Mil.
Total Current Liabilities was $0.23 Mil.
Net Income was -0.485 + -0.363 + 0 + 0 = $-0.85 Mil.

Revenue was 0.044 + 0.095 + 0 + 0 = $0.14 Mil.
Gross Profit was -0.027 + 0.095 + 0 + 0 = $0.07 Mil.
Average Total Assets from the begining of last year (Mar05)
to the end of last year (Dec19) was
(1.044 + 1.003 + 0.871 + 10.15 + 17.172) / 5 = $6.048 Mil.
Total Assets at the begining of last year (Mar05) was $1.04 Mil.
Long-Term Debt & Capital Lease Obligation was $8.46 Mil.
Total Current Assets was $0.25 Mil.
Total Current Liabilities was $1.46 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Easton Pharmaceuticals's current Net Income (TTM) was -0.26. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Easton Pharmaceuticals's current Cash Flow from Operations (TTM) was -0.14. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec19)
=-0.261/17.172
=-0.01519916

ROA (Last Year)=Net Income/Total Assets (Mar05)
=-0.848/1.044
=-0.81226054

Easton Pharmaceuticals's return on assets of this year was -0.01519916. Easton Pharmaceuticals's return on assets of last year was -0.81226054. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Easton Pharmaceuticals's current Net Income (TTM) was -0.26. Easton Pharmaceuticals's current Cash Flow from Operations (TTM) was -0.14. ==> -0.14 > -0.26 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec19 to Sep21
=2.837/11.4122
=0.24859361

Gearing (Last Year: Dec19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar05 to Dec19
=8.459/6.048
=1.39864418

Easton Pharmaceuticals's gearing of this year was 0.24859361. Easton Pharmaceuticals's gearing of last year was 1.39864418. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep21)=Total Current Assets/Total Current Liabilities
=0/0.233
=0

Current Ratio (Last Year: Dec19)=Total Current Assets/Total Current Liabilities
=0.25/1.455
=0.17182131

Easton Pharmaceuticals's current ratio of this year was 0. Easton Pharmaceuticals's current ratio of last year was 0.17182131. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Easton Pharmaceuticals's number of shares in issue this year was 1344.932. Easton Pharmaceuticals's number of shares in issue last year was 1344.932. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.068/0.139
=0.48920863

Easton Pharmaceuticals's gross margin of this year was . Easton Pharmaceuticals's gross margin of last year was 0.48920863. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec19)
=0/17.172
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar05)
=0.139/1.044
=0.13314176

Easton Pharmaceuticals's asset turnover of this year was 0. Easton Pharmaceuticals's asset turnover of last year was 0.13314176. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Easton Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Easton Pharmaceuticals  (OTCPK:EAPH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Easton Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Easton Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Easton Pharmaceuticals (Easton Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8
Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.

Easton Pharmaceuticals (Easton Pharmaceuticals) Headlines

From GuruFocus

Easton Pharmaceuticals Announces BAYER Agreement Update

By Marketwired Marketwired 04-16-2018